<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25111" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Microscopic Polyangiitis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hashmi</surname>
            <given-names>Muhammad F.</given-names>
          </name>
          <aff>National Health Service</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jain</surname>
            <given-names>Vardhmaan</given-names>
          </name>
          <aff>Atlanta</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rout</surname>
            <given-names>Preeti</given-names>
          </name>
          <aff>Wilson Case Western University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Hashmi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vardhmaan Jain declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Rout declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>31</day>
          <month>8</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25111.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Microscopic polyangiitis (MPA) is a small vessel necrotizing vasculitis that falls within a larger spectrum of disorders known as antineutrophil cytoplasmic antibody (ANCA)&#x02013;associated vasculitides. This group also includes granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis, MPA, and renal-limited vasculitis. MPA is a complex disorder that can affect any organ system, presenting with a wide range of symptoms.</p>
        <p>Early diagnosis and treatment are crucial for improving outcomes, as immunosuppressive therapy is most effective when initiated before significant organ damage occurs. Treatment is typically divided into induction and maintenance phases, utilizing medications such as cyclophosphamide, glucocorticoids, and rituximab. Numerous trials have explored the most effective treatment regimens for various clinical scenarios. A comprehensive evaluation&#x02014;including clinical, radiological, histopathological, and laboratory assessments&#x02014;is essential for accurate diagnosis and effective management.&#x000a0;This activity reviews the etiology, epidemiology, pathogenesis, histological findings, evaluation, and management of MPA, emphasizing the critical role of the interprofessional team in recognizing and managing this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify early clinical signs and symptoms of microscopic polyangiitis to facilitate timely diagnosis and intervention.</p></list-item><list-item><p>Implement evidence-based treatment regimens for microscopic&#x000a0;polyangiitis, including induction and maintenance therapies with cyclophosphamide, glucocorticoids, and rituximab.</p></list-item><list-item><p>Select appropriate diagnostic tests and imaging studies to evaluate organ involvement and disease activity in patients with microscopic&#x000a0;polyangiitis.</p></list-item><list-item><p>Collaborate with an interprofessional team to provide comprehensive care for patients with microscopic polyangiitis and address any complications or relapses.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25111&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25111">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25111.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Microscopic polyangiitis (MPA) is a small vessel necrotizing vasculitis that falls within a&#x000a0;larger spectrum of disorders known as antineutrophil cytoplasmic antibody (ANCA)&#x02013;associated vasculitides. This group also includes granulomatosis with polyangiitis (GPA), MPA, eosinophilic granulomatosis with polyangiitis (EGPA or Churg-Strauss disease), and renal limited&#x000a0;vasculitis. This classification of vasculitides is based on the type of vessels involved and the underlying etiology, as established by the International Chapel Hill Consensus Conference on the Nomenclature of Vasculitides (CHCC 2012).<xref ref-type="bibr" rid="article-25111.r1">[1]</xref></p>
        <p>The term "microscopic polyangiitis" was&#x000a0;first described as "microscopic polyarteritis" and introduced in the literature by Davson&#x000a0;in 1948 to describe the pattern of glomerulonephritis observed in patients with polyarteritis nodosa. This condition was later described as a pattern of necrotizing vasculitis without immune complex deposition, primarily affecting small vessels such as the capillaries, venules, and arterioles. The disease commonly involves glomerulonephritis, pulmonary capillaritis, and other systemic capillary beds, with considerable overlap with GPA.</p>
        <p>The absence of granulomatous inflammation in the upper respiratory tract and the presence of pulmonary capillaritis help differentiate MPA from GPA. MPA is more likely to have renal involvement than GPA. MPA is part of a group of disorders known as pulmonary-renal syndrome, which also includes GPA, Goodpasture disease, and systemic lupus erythematosus.<xref ref-type="bibr" rid="article-25111.r2">[2]</xref><xref ref-type="bibr" rid="article-25111.r3">[3]</xref>&#x000a0;While&#x000a0;ANCAs have a central role in the pathogenesis of ANCA-associated vasculitis, they are neither necessary nor sufficient to cause the disease patterns of ANCA-associated vasculitides. Clinical symptoms and biopsy results are equally important for diagnosis. The role of ANCAs and the distinctions between the various ANCA-associated vasculitides are also discussed in this activity.&#x000a0;</p>
        <p>Please refer to the following StatPearls' companion resources for further&#x000a0;information:</p>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/76416">Granulomatosis With Polyangiitis</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/19543">Eosinophilic Granulomatosis With Polyangiitis</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/32717">ANCA-Associated Vasculitis</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/22288">Rapidly Progressive Glomerulonephritis</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/20240">Antineutrophil Cytoplasmic Antibodies ANCA Test</ext-link>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25111.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiopathogenesis of MPA and related vasculitides has largely been attributed to ANCAs, which are host-derived autoantibodies targeting normally shielded neutrophilic antigens. These antibodies react against primary granules in neutrophils and monocytes. The formation of these antibodies has been hypothesized to be a 2-step process.<xref ref-type="bibr" rid="article-25111.r4">[4]</xref>&#x000a0;In&#x000a0;the first step, neutrophils are exposed to inflammatory cytokines, leading to the surface expression of antigens such as myeloperoxidase (MPO). Next, predisposing genetic, environmental, and other factors lead to ANCA production. In the second step, these ANCAs damage the host vasculature by triggering inflammation and cytokine production.<xref ref-type="bibr" rid="article-25111.r5">[5]</xref></p>
        <p>Although anti-MPO is the primary ANCA associated with MPA, anti-proteinase 3 (PR3) can also be present in some cases. Estimates suggest that approximately 70% of patients with MPA are anti-MPO&#x02013;positive, 20% are anti-PR3&#x02013;positive, and 10% are ANCA-negative.<xref ref-type="bibr" rid="article-25111.r6">[6]</xref> Less specific ANCA antigens include cathepsin G, lactoferrin, elastase, defensin, &#x003b1;-enolase, moesin, leukocidin, and bactericidal permeability increasing protein, although their pathogenicity is considered to be low.<xref ref-type="bibr" rid="article-25111.r6">[6]</xref></p>
        <p>Lysosomal-associated membrane protein 2 (LAMP-2) antibodies are of particular interest in ANCA-associated vasculitis because they are present in patients with both anti-MPO and anti-PR3 antibodies and may contribute to the disease pathology. Moreover, LAMP-2 antibodies have been detected in patients with active ANCA-associated vasculitis who are negative for MPO and PR3 antibodies. Some evidence suggests that LAMP-2 antibodies may correlate better with disease activity than anti-MPO or anti-PR3 antibodies.<xref ref-type="bibr" rid="article-25111.r7">[7]</xref><xref ref-type="bibr" rid="article-25111.r8">[8]</xref></p>
        <p>About 90% of patients with active MPA test positive for ANCA; however, not all cases of ANCA positivity correlate with active disease. This suggests that other factors may also contribute to the disease's etiopathogenesis. These factors include (but are not limited to):</p>
        <list list-type="bullet">
          <list-item>
            <p>Infectious causes: The considerable overlap between the clinical presentations of various infectious processes and MPA leads to this implication. Chronic nasal carriage of <italic toggle="yes">Staphylococcus aureus</italic> has been proposed as a potential contributing factor.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Genetic factors: Recent genome-wide studies conducted in Europe have identified genes such as&#x000a0;<italic toggle="yes">HLA-DP</italic>, <italic toggle="yes">HLA-DR3</italic>, and alpha-1 antitrypsin as potentially involved in the pathogenesis of ANCA-associated vasculitis.<xref ref-type="bibr" rid="article-25111.r9">[9]</xref><xref ref-type="bibr" rid="article-25111.r10">[10]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Environmental factors: UV light, air pollution, and silica exposure have also been suggested as possible triggers for ANCA-associated vasculitis.<xref ref-type="bibr" rid="article-25111.r8">[8]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Drugs: Certain medications, including hydralazine, thionamides, sulfasalazine, and minocycline, have been observed to be associated with the incidence of ANCA-associated vasculitis.<xref ref-type="bibr" rid="article-25111.r10">[10]</xref><xref ref-type="bibr" rid="article-25111.r11">[11]</xref>&#x000a0;This form of vasculitis is often anti-MPO positive and is covered more extensively in the StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/32717">ANCA-Associated Vasculitis</ext-link>."</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25111.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Due to the recent differentiation of MPA from other ANCA-associated vasculitides, comprehensive demographic data for its prevalence in the US population are not widely available. A study conducted in Rochester, Minnesota, over a 20-year period estimated the annual incidence of ANCA-associated vasculitis&#x000a0;at 3.3 per 100,000, with a prevalence of 42.1 per 100,000. The incidence of GPA and MPA was approximately 1.5 per 100,000.<xref ref-type="bibr" rid="article-25111.r12">[12]</xref>&#x000a0;An increase in the prevalence of MPA over the past 2 decades is likely due to improved recognition and the availability of ANCA testing. The global incidence of MPA is estimated to be 20 per million.<xref ref-type="bibr" rid="article-25111.r6">[6]</xref>&#x000a0;</p>
        <p>Evidence suggests that MPA is more common in China and Japan, whereas GPA is more prevalent among populations of European descent.<xref ref-type="bibr" rid="article-25111.r6">[6]</xref>&#x000a0;The median age of onset for MPA is between 50&#x000a0;and 60. The disease appears to have about equal prevalence between males and females.<xref ref-type="bibr" rid="article-25111.r8">[8]</xref></p>
      </sec>
      <sec id="article-25111.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>While anti-MPO is the primary ANCA associated with MPA, anti-PR3 is also present in some cases. Notably, it is estimated that in MPA, approximately 70% of patients are anti-MPO&#x02013;positive, 20% are anti-PR3&#x02013;positive, and 10% are ANCA-negative.<xref ref-type="bibr" rid="article-25111.r6">[6]</xref>&#x000a0;</p>
        <p>The clinical manifestations of MPA result from the activation of primed neutrophils and MPO-ANCA, which interact with receptors on the endothelial surface.<xref ref-type="bibr" rid="article-25111.r13">[13]</xref>&#x000a0;This&#x000a0;process leads to a range of symptoms affecting the renal, pulmonary, and other capillary beds. Patients may present with an insidious onset of systemic signs such as fever, malaise, or weight loss; however, the onset is more commonly acute, with complaints of arthralgia and flu-like symptoms. MPA is a small vessel vasculitis characterized by pauci-immune, necrotizing inflammation without clinical or pathological evidence of granulomatous involvement, often leading to necrosis and bleeding.<xref ref-type="bibr" rid="article-25111.r6">[6]</xref>&#x000a0;</p>
        <p>Renal manifestations are extremely common in MPA, with 80% to 90% of individuals experiencing some form of glomerulonephritis at onset or as the disease progresses. The most common renal manifestation is a "pauci-immune" form of rapidly progressive glomerulonephritis. Clinical presentations can range from asymptomatic hematuria, sub-nephrotic proteinuria, and elevated serum creatinine to overt renal failure. Pulmonary manifestations often include alveolar hemorrhage, which may sometimes be the first presenting symptom of the disease.<xref ref-type="bibr" rid="article-25111.r14">[14]</xref></p>
      </sec>
      <sec id="article-25111.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histopathological evidence of vasculitis is the gold standard for confirming the diagnosis of MPA and other ANCA-associated vasculitides. The most commonly sampled tissues are from the kidneys, skin, and lungs. Diffuse capillaritis is a typical pulmonary finding in patients with MPA, distinguishing it from GPA, which is characterized by the presence of granulomatous lesions. Skin biopsy yields acute or chronic leukocytoclastic vasculitis with neutrophilic infiltrate in the narrow caliber vessels of the superficial dermis. Renal biopsy&#x000a0;findings in MPA typically range from mild focal or segmental to diffuse necrotizing and sclerosing glomerulonephritis, often presenting as crescentic glomerulonephritis. These biopsies usually show minimal to no immune complex deposits on light and immunofluorescent microscopy, a characteristic described as "pauci-immune" (see <bold>Image.</bold> Histopathological Changes in Microscopic Polyangiitis Showing Fibrosis).<xref ref-type="bibr" rid="article-25111.r15">[15]</xref>&#x000a0;</p>
        <p>The importance of renal biopsy is underscored by the fact that the severity of renal involvement observed on histopathological evaluation correlates closely with clinical disease activity.<xref ref-type="bibr" rid="article-25111.r16">[16]</xref> This makes biopsy a crucial tool for guiding the management of the condition and decisions regarding tapering immunosuppressive therapy. In some cases, the presence of immune complex deposits in the glomeruli may be associated with more severe systemic signs and symptoms. Please see StatPearls' companion resource, "<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/point-of-care/22288">Rapidly Progressive Glomerulonephritis</ext-link>," for more information.</p>
      </sec>
      <sec id="article-25111.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with&#x000a0;MPA may present with constitutional symptoms, including insidious onset fever, arthralgia, myalgia, and weight loss. Other manifestations include urinary abnormalities, cough with or without hemoptysis, skin examination findings consistent with palpable purpura, mononeuritis multiplex, seizures, other nonspecific neurological complaints, abdominal pain, gastrointestinal bleeding, sinusitis, and chest,&#x000a0;testicular, and ocular pain. Some patients may present with acute onset of fulminant disease with frank hemoptysis, hematuria, or even renal failure.</p>
        <p>
<bold>Renal Manifestations</bold>
</p>
        <p>The primary renal feature of MPA is rapidly progressive glomerulonephritis.<xref ref-type="bibr" rid="article-25111.r17">[17]</xref> Previous studies reported that 80% to 90% of patients with MPA experience renal manifestations, which can range from asymptomatic urinary sediment to end-stage renal failure requiring renal replacement therapy. Common clinical features of renal involvement due to glomerulonephritis include microscopic hematuria, proteinuria, and the presence of granular or red blood cell (RBC) casts in the urine.<xref ref-type="bibr" rid="article-25111.r18">[18]</xref></p>
        <p>
<bold>Pulmonary Manifestations</bold>
</p>
        <p>Pulmonary involvement is thought to be observed in 25% to 55% of cases. However, pulmonary symptoms may be more common than previously thought. A single-center study found that 80% of MPA patients were observed to have symptoms of pulmonary involvement, and 92% were found to have radiographic changes.<xref ref-type="bibr" rid="article-25111.r19">[19]</xref>&#x000a0;Although the most&#x000a0;common pulmonary&#x000a0;feature is diffuse alveolar hemorrhage, some patients may develop&#x000a0;chronic interstitial fibrosis, causing respiratory failure.<xref ref-type="bibr" rid="article-25111.r20">[20]</xref>&#x000a0;Common&#x000a0;manifestations&#x000a0;of alveolar hemorrhage include hemoptysis, cough, dyspnea, and pleuritic chest pain.<xref ref-type="bibr" rid="article-25111.r21">[21]</xref>&#x000a0;Unlike GPA and EGPA, upper respiratory tract signs are rare.</p>
        <p>
<bold>Skin Manifestations</bold>
</p>
        <p>Skin lesions are observed in 30% to 60% of patients with MPA, and these lesions are the initial presenting feature in 15% to 30% of cases.<xref ref-type="bibr" rid="article-25111.r22">[22]</xref><xref ref-type="bibr" rid="article-25111.r23">[23]</xref> These skin manifestations include palpable purpura, livedo reticularis, urticaria, nodules, and ulcers with necrosis. Additionally, skin manifestations have been associated with joint pain in patients with MPA (see <bold>Image.</bold> Typical Skin Manifestations Observed in Microscopic Polyangiitis).<xref ref-type="bibr" rid="article-25111.r24">[24]</xref></p>
        <p>
<bold>Gastrointestinal Manifestations</bold>
</p>
        <p>Abdominal pain is the most common gastrointestinal symptom in MPA. Although gastrointestinal bleeding can occur, massive hemorrhage is rare.<xref ref-type="bibr" rid="article-25111.r25">[25]</xref></p>
        <p>
<bold>Neurological Manifestations</bold>
</p>
        <p>Neurological involvement is common in MPA, with peripheral neuropathy occurring more frequently than central nervous system (CNS) involvement. Predominant peripheral nervous system features include distal symmetrical polyneuropathy and mononeuritis multiplex. Sural nerve biopsies often reveal necrotizing vasculitis in up to 80% of cases, and nerve conduction studies may show acute axonopathy.<xref ref-type="bibr" rid="article-25111.r26">[26]</xref> Rarely, patients may present with&#x000a0;posterior reversible encephalopathy syndrome.<xref ref-type="bibr" rid="article-25111.r27">[27]</xref>&#x000a0;CNS manifestations can vary and include cerebral hemorrhage, nonhemorrhagic cerebral infarctions, and pachymeningitis.<xref ref-type="bibr" rid="article-25111.r28">[28]</xref></p>
        <p>
<bold>Physical Examination</bold>
</p>
        <p>Findings from the physical examination of a patient with MPA may reveal systemic signs such as general malaise, fever, or weight loss. Skin examination findings may include leukocytoclastic angiitis, palpable purpura, livedo reticularis, skin ulcerations, necrosis, gangrene, necrotizing nodules, digital ischemia, and urticaria. Pulmonary examination may reveal rales or bronchial breath sounds, particularly in cases of pulmonary capillaritis. Neurological examination might demonstrate motor or sensory deficits localized to a particular dermatome. Cardiovascular findings may include hypertension, signs of heart failure, myocardial infarction, and pericarditis. Findings from the gastrointestinal examination include bleeding, bowel ischemia, and perforation. The ocular examination may reveal retinal hemorrhage, scleritis, and uveitis. Other physical findings will vary depending on the involved vascular bed.</p>
      </sec>
      <sec id="article-25111.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Evaluating a patient with suspected MPA requires a comprehensive clinical, radiological, histopathological, and laboratory assessment. The initial step is a detailed clinical evaluation to determine the site and extent of involvement across various organ systems.</p>
        <p>
<bold>Laboratory Studies</bold>
</p>
        <p>As noted above, although anti-MPO is the primary ANCA associated with MPA, anti-PR3 can also be present in some cases. ANCA levels are most closely correlated with renal activity compared to other organ systems.<xref ref-type="bibr" rid="article-25111.r8">[8]</xref>&#x000a0;Other useful laboratory evaluations include:</p>
        <list list-type="bullet">
          <list-item>
            <p>The complete blood cell count (CBC) shows leukocytosis and anemia.</p>
          </list-item>
          <list-item>
            <p>The erythrocyte sedimentation rate (ESR) is usually elevated.</p>
          </list-item>
          <list-item>
            <p>Blood urea nitrogen (BUN) and serum creatinine levels are elevated in cases of renal failure.</p>
          </list-item>
          <list-item>
            <p>Urine examination shows abnormal urine sediment, proteinuria, hematuria, leukocyturia, and RBC casts.</p>
          </list-item>
          <list-item>
            <p>Blood cultures may be performed to rule out bacterial endocarditis.</p>
          </list-item>
          <list-item>
            <p>C3 and C4 levels are usually normal on complement testing.</p>
          </list-item>
        </list>
        <p>
<bold>Imaging Studies</bold>
</p>
        <p>A chest radiography and computed tomography (CT) scan of the chest should be obtained to assess for pulmonary lesions in patients presenting with hemoptysis or pulmonary fibrosis.<xref ref-type="bibr" rid="article-25111.r29">[29]</xref>&#x000a0;These imaging studies help differentiate between GPA and MPA, as GPA often shows cavitary and nodular lesions on radiological evaluation. A CT scan of the abdomen may also be performed to evaluate for pancreatitis or mesenteric angiography to distinguish MPA from polyarteritis nodosa.<xref ref-type="bibr" rid="article-25111.r30">[30]</xref></p>
        <p>
<bold>Other&#x000a0;Studies</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Electrocardiography (ECG) is used&#x000a0;to evaluate for myocardial infarction, pericarditis, or heart failure.</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal endoscopy is performed in cases of gastrointestinal bleeding.</p>
          </list-item>
          <list-item>
            <p>Electromyography (EMG) and nerve conduction studies are utilized in cases of clinical evidence of neuropathy.<xref ref-type="bibr" rid="article-25111.r31">[31]</xref></p>
          </list-item>
        </list>
        <p><bold>Histopathological Evaluation</bold>&#x000a0;</p>
        <p>A histopathological specimen (skin, renal, or lung biopsy) should be obtained whenever possible to identify evidence of vasculitis and immune deposits. The extent of inflammation observed on renal biopsy can be used to assess disease activity and guide treatment decisions.</p>
      </sec>
      <sec id="article-25111.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Currently, the American College of Rheumatology and the European Alliance of Associations for Rheumatology (ACR/EULAR) are developing criteria for the treatment of ANCA-associated vasculitis. Based on new clinical trial data, recent recommendations suggest classifying disease manifestations into organ/life-threatening or non-organ/life-threatening categories rather than "severe" or "not severe." Examples of organ/life-threatening manifestations include glomerulonephritis, pulmonary hemorrhage, cardiac involvement, and retroorbital disease. Non-organ/life-threatening manifestations include skin involvement, myositis, and non-cavitating pulmonary nodules.<xref ref-type="bibr" rid="article-25111.r32">[32]</xref></p>
        <p>The treatment of MPA involves using immunosuppressive agents in various combinations, divided into two phases: induction and maintenance. Commonly used agents include cyclophosphamide, glucocorticoids, rituximab, azathioprine, methotrexate, and, when indicated, plasmapheresis.&#x000a0;</p>
        <p>The 2022 EULAR recommendations for the management of&#x000a0;ANCA-associated vasculitis apply to both GPA and MPA.<xref ref-type="bibr" rid="article-25111.r32">[32]</xref>&#x000a0;Treating EGPA follows a different set of guidelines. A key distinction between GPA and MPA is that patients with the clinical syndrome of GPA and PR3-ANCA positivity have a higher relapse risk compared to those with MPA or anti-MPO positivity. Additionally, persistent ANCA positivity, despite clinical remission, is associated with an increased risk of relapse.<xref ref-type="bibr" rid="article-25111.r32">[32]</xref>&#x000a0;Although&#x000a0;extending immunosuppressive therapy beyond 24 months may reduce relapse risk, the heightened risk of infection may not warrant this prolonged treatment course.</p>
        <p>The 2022 EULAR recommendations include:</p>
        <list list-type="bullet">
          <list-item>
            <p>For&#x000a0;new-onset organ/life-threatening MPA and GPA, remission should be induced with glucocorticoids combined with either rituximab or cyclophosphamide. Rituximab is preferred in cases of relapsing disease. No significant differences are observed in outcomes between using 2-dose or 4-dose infusions of rituximab.<xref ref-type="bibr" rid="article-25111.r33">[33]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For new-onset non-organ/life-threatening MPA, remission should be induced with glucocorticoids and rituximab. In some cases, methotrexate or mycophenolate mofetil can be substituted for rituximab. Cyclophosphamide is generally not preferred due to a higher incidence of adverse effects despite its reduced efficacy. Additionally, a lower prednisolone dose of 0.5 mg/kg/d may also be considered.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The induction regimen should include oral glucocorticoids at a weight-dependent dose of 50 to 75 mg daily, with prednisolone tapered to 5 mg daily over 4 to 5 months.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Avacopan is an oral C5a-receptor antagonist that helps block neutrophil attraction and activation. The ADVOCATE trial demonstrated that avacopan can induce remission when used alongside rituximab or cyclophosphamide, reducing the need for glucocorticoid exposure. Avacopan was approved by the US Food and Drug Administration (FDA) in 2021 to treat severe ANCA-associated vasculitis.<xref ref-type="bibr" rid="article-25111.r34">[34]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Plasma exchange can induce remission in patients with glomerulonephritis and a serum creatinine level greater than 3.39 mg/dL (300 &#x003bc;mol/L). Routine use of plasmapheresis for alveolar hemorrhage in MPA and GPA is not recommended. However, it is often used as "salvage" therapy, particularly for patients with a serum creatinine level exceeding 5.7 mg/dL.<xref ref-type="bibr" rid="article-25111.r35">[35]</xref>&#x000a0;A meta-analysis suggests that plasmapheresis reduces the risk of end-stage renal disease but is associated with an increased risk of infections within the first year.<xref ref-type="bibr" rid="article-25111.r36">[36]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Rituximab is recommended for maintaining remission. Azathioprine or methotrexate may also be considered; however, their use should be reserved for patients with an estimated glomerular filtration rate greater than 60 mL/min/1.73m<sup>2</sup>.<xref ref-type="bibr" rid="article-25111.r35">[35]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For new-onset disease, maintenance therapy should continue for 24 to 48 months after remission begins. A longer treatment duration should be considered for patients with relapsing disease.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Treatment decisions should be guided by clinical assessment rather than ANCA levels or CD19+ B lymphocyte counts.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>If rituximab is administered, serum immunoglobulin levels should be measured before each dose.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For patients receiving rituximab, cyclophosphamide, or high-dose glucocorticoids, prophylaxis with trimethoprim-sulfamethoxazole should be provided.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25111.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Many conditions may mimic ANCA-associated vasculitis/MPA and must be excluded before establishing a diagnosis. Some of these processes include:</p>
        <p>
<bold>Infectious Etiologies</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Infective endocarditis</p>
          </list-item>
          <list-item>
            <p>Rocky Mountain spotted fever and other tick-borne vasculitides</p>
          </list-item>
          <list-item>
            <p>Disseminated&#x000a0;fungal infections</p>
          </list-item>
        </list>
        <p>
<bold>Malignancies</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Atrial myxomas</p>
          </list-item>
          <list-item>
            <p>Lymphomas</p>
          </list-item>
          <list-item>
            <p>Carcinomatosis</p>
          </list-item>
        </list>
        <p>
<bold>Drug Toxicities</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Cocaine</p>
          </list-item>
          <list-item>
            <p>Amphetamines</p>
          </list-item>
          <list-item>
            <p>Ergot alkaloids</p>
          </list-item>
          <list-item>
            <p>Levamisole</p>
          </list-item>
        </list>
        <p>
<bold>Other Autoimmune Conditions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Amyloidosis</p>
          </list-item>
          <list-item>
            <p>Goodpasture disease&#x000a0;<xref ref-type="bibr" rid="article-25111.r37">[37]</xref></p>
          </list-item>
          <list-item>
            <p>Sarcoidosis</p>
          </list-item>
          <list-item>
            <p>Polyarteritis nodosa</p>
          </list-item>
          <list-item>
            <p>Leukocytoclastic vasculitis</p>
          </list-item>
          <list-item>
            <p>Granulomatosis with polyangiitis</p>
          </list-item>
          <list-item>
            <p>Eosinophilic granulomatosis with polyangiitis</p>
          </list-item>
          <list-item>
            <p>Cryoglobulinemia</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25111.s11" sec-type="Toxicity and Adverse Effect Management">
        <title>Toxicity and Adverse Effect Management</title>
        <p>The immunosuppressive agents used in managing&#x000a0;ANCA-associated vasculitis have severe adverse&#x000a0;effects, which may be even more debilitating than the manifestations of the disease.&#x000a0;</p>
        <p>
<bold>Glucocorticoids</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Osteoporosis&#x000a0;<xref ref-type="bibr" rid="article-25111.r38">[38]</xref></p>
          </list-item>
          <list-item>
            <p>Cataract</p>
          </list-item>
          <list-item>
            <p>Glaucoma</p>
          </list-item>
          <list-item>
            <p>Diabetes mellitus</p>
          </list-item>
          <list-item>
            <p>Electrolyte abnormalities</p>
          </list-item>
          <list-item>
            <p>Avascular necrosis of bone</p>
          </list-item>
        </list>
        <p>
<bold>Cyclophosphamide</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bone marrow suppression</p>
          </list-item>
          <list-item>
            <p>Hemorrhagic cystitis&#x000a0;<xref ref-type="bibr" rid="article-25111.r39">[39]</xref></p>
          </list-item>
          <list-item>
            <p>Bladder carcinoma</p>
          </list-item>
          <list-item>
            <p>Myelodysplasia</p>
          </list-item>
        </list>
        <p>
<bold>Methotrexate</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hepatotoxicity</p>
          </list-item>
          <list-item>
            <p>Pneumonitis</p>
          </list-item>
          <list-item>
            <p>Bone marrow suppression</p>
          </list-item>
        </list>
        <p>
<bold>Azathioprine</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hepatotoxicity</p>
          </list-item>
          <list-item>
            <p>Bone marrow suppression</p>
          </list-item>
        </list>
        <p>
<bold>Rituximab</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Progressive multifocal leukoencephalopathy</p>
          </list-item>
          <list-item>
            <p>Opportunistic infections</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25111.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The 5-year estimated survival rate for patients with MPA ranges from 45% to 76%, which is significantly worse than that for GPA or EGPA, largely due to renal disease.<xref ref-type="bibr" rid="article-25111.r6">[6]</xref><xref ref-type="bibr" rid="article-25111.r40">[40]</xref></p>
        <p>Long-term morbidity in a&#x000a0;cohort of 296 patients with MPA or GPA was associated with the severity of the primary disease, the number of relapses, older age, and the duration of glucocorticoid treatment. In a 7-year follow-up post-diagnosis, the mean duration of glucocorticoid therapy was 40.4 months.<xref ref-type="bibr" rid="article-25111.r41">[41]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-25111.s13" sec-type="Complications">
        <title>Complications</title>
        <p>If left untreated, MPA can lead to permanent organ damage, with kidney failure being the most common complication. Other complications depend on the specific organ systems involved. Research has shown that older age, diastolic hypertension, and positive PR3-ANCA status correlate with an increased risk of cardiovascular events.<xref ref-type="bibr" rid="article-25111.r42">[42]</xref></p>
        <p>The medications used to treat MPA can also lead to significant adverse effects. For instance, cyclophosphamide is strongly associated with an increased risk of bladder cancer. Additionally, steroids are known to cause bone loss, hyperglycemia, muscle weakness, and skin issues.</p>
      </sec>
      <sec id="article-25111.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Adherence to medication and therapy is crucial, along with regular follow-ups. Patients should be closely monitored during the prolonged course of immunosuppressive treatment, which typically extends for over a year, with disease activity assessed through ANCA levels. It's essential to inform patients about the potential adverse effects of their medications and emphasize the importance of reporting them promptly. Additionally, patients should be made aware that relapse is common, so they understand the necessity of ongoing follow-up even after achieving remission, as they are not "cured."</p>
      </sec>
      <sec id="article-25111.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>MPA is a complex condition best managed by a multidisciplinary team due to its varied clinical presentation and the need for patient-specific treatment. Effective communication among an interprofessional medical team&#x02014;including clinicians, nurses, radiologists, pathologists, and pharmacists&#x02014;is essential for optimal care. Nurses are critical in monitoring and documenting vital signs, especially urine output, which is crucial for guiding treatment decisions. Radiologists contribute by performing image-guided tissue biopsies, which are then analyzed by pathologists to confirm the presence of disease. Proper dosing and dispensing of immunosuppressive agents by pharmacists are crucial for the successful induction and maintenance of remission. Failure in this area can result in severe systemic adverse effects. Additionally, pharmacists must perform thorough medication reconciliation to prevent potential drug-drug interactions.</p>
        <p>To determine the appropriate treatment, researchers at Johns Hopkins University have developed the revised Birmingham score, which can be used to clinically classify the patient's disease state.<xref ref-type="bibr" rid="article-25111.r43">[43]</xref>&#x000a0;All interprofessional healthcare team members must maintain accurate, updated patient records, ensuring all professionals involved in patient care have access to the same patient information. Open communication channels between all healthcare team members are crucial to successful interprofessional care.</p>
        <p>In addition, care coordination is pivotal in ensuring seamless and efficient patient care. Physicians, advanced practitioners, nurses, pharmacists, social workers, and other healthcare professionals must collaborate closely to streamline the patient's journey, from diagnosis through treatment and follow-up. This coordination minimizes errors, reduces delays, and enhances patient safety, ultimately leading to improved outcomes and patient-centered care that prioritizes the well-being and satisfaction of those affected by MPA.</p>
      </sec>
      <sec id="article-25111.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25111&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25111">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/microscopic-polyangiitis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25111">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25111/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25111">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-25111.s17">
        <fig id="article-25111.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Histopathological Changes in Microscopic Polyangiitis Showing Fibrosis. Contributed by Rian Kabir, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Kabir_Microscopic__Polyangiitis__Path" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-25111.s18">
        <fig id="article-25111.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Typical Skin Manifestations Observed in Microscopic Polyangiitis. Contributed by R Kabir, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Kabir_Microscopic__Polyangiitis__Rash" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-25111.s19">
        <title>References</title>
        <ref id="article-25111.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jennette</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Bacon</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Basu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cid</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Ferrario</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Flores-Suarez</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Guillevin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hagen</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Kallenberg</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Lamprecht</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Langford</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Luqmani</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Mahr</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Matteson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Ozen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pusey</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rees</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Specks</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.</article-title>
            <source>Arthritis Rheum</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>65</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-11</page-range>
            <pub-id pub-id-type="pmid">23045170</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chung</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Seo</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Microscopic polyangiitis.</article-title>
            <source>Rheum Dis Clin North Am</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>36</volume>
            <issue>3</issue>
            <fpage>545</fpage>
            <page-range>545-58</page-range>
            <pub-id pub-id-type="pmid">20688249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rizzo</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>De Virgilio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gallo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fusconi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pagliuca</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Martellucci</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Turchetta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Longo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>De Vincentiis</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Goodpasture's syndrome: a clinical update.</article-title>
            <source>Autoimmun Rev</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>246</fpage>
            <page-range>246-53</page-range>
            <pub-id pub-id-type="pmid">25462583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kallenberg</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Heeringa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stegeman</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides.</article-title>
            <source>Nat Clin Pract Rheumatol</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>2</volume>
            <issue>12</issue>
            <fpage>661</fpage>
            <page-range>661-70</page-range>
            <pub-id pub-id-type="pmid">17133251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Lind van Wijngaarden</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>van Rijn</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hagen</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Gregorini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tervaert</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Mahr</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Niles</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>de Heer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bruijn</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Bajema</surname>
                <given-names>IM</given-names>
              </name>
            </person-group>
            <article-title>Hypotheses on the etiology of antineutrophil cytoplasmic autoantibody associated vasculitis: the cause is hidden, but the result is known.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>237</fpage>
            <page-range>237-52</page-range>
            <pub-id pub-id-type="pmid">18077783</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walulik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>&#x00141;ysak</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>B&#x00142;aszkiewicz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>G&#x000f3;recki</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gomu&#x00142;ka</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The Role of Neutrophils in ANCA-Associated Vasculitis: The Pathogenic Role and Diagnostic Utility of Autoantibodies.</article-title>
            <source>Int J Mol Sci</source>
            <year>2023</year>
            <month>Dec</month>
            <day>07</day>
            <volume>24</volume>
            <issue>24</issue>
            <pub-id pub-id-type="pmid">38139045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kain</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tadema</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>McKinney</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Benharkou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brandes</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Peschel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hubert</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Feenstra</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Seng&#x000f6;lge</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stegeman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Heeringa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lyons</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Kallenberg</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rees</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>556</fpage>
            <page-range>556-66</page-range>
            <pub-id pub-id-type="pmid">22323643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jennette</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Nachman</surname>
                <given-names>PH</given-names>
              </name>
            </person-group>
            <article-title>ANCA Glomerulonephritis and Vasculitis.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2017</year>
            <month>Oct</month>
            <day>06</day>
            <volume>12</volume>
            <issue>10</issue>
            <fpage>1680</fpage>
            <page-range>1680-1691</page-range>
            <pub-id pub-id-type="pmid">28842398</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lyons</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Rayner</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Trivedi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Holle</surname>
                <given-names>JU</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Baslund</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brenchley</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bruchfeld</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chaudhry</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Cohen Tervaert</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Deloukas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Feighery</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Guillevin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gunnarsson</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hru&#x00161;kov&#x000e1;</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Little</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Martorana</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Neumann</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ohlsson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Padmanabhan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pusey</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Salama</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Segelmark</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stegeman</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Tesa&#x00159;</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Vaglio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wieczorek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wilde</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zwerina</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rees</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Clayton</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>KG</given-names>
              </name>
            </person-group>
            <article-title>Genetically distinct subsets within ANCA-associated vasculitis.</article-title>
            <source>N Engl J Med</source>
            <year>2012</year>
            <month>Jul</month>
            <day>19</day>
            <volume>367</volume>
            <issue>3</issue>
            <fpage>214</fpage>
            <page-range>214-23</page-range>
            <pub-id pub-id-type="pmid">22808956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wakamatsu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mitsuhashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tsuboi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Propylthiouracil-induced antineutrophil cytoplasmic antibody positive vasculitis clinically mimicking pyoderma gangrenosum.</article-title>
            <source>J Dermatol</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>39</volume>
            <issue>8</issue>
            <fpage>736</fpage>
            <page-range>736-8</page-range>
            <pub-id pub-id-type="pmid">22132781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pendergraft</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Niles</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis.</article-title>
            <source>Curr Opin Rheumatol</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>42</fpage>
            <page-range>42-9</page-range>
            <pub-id pub-id-type="pmid">24276086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cornec</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Crowson</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Specks</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Matteson</surname>
                <given-names>EL</given-names>
              </name>
            </person-group>
            <article-title>The Epidemiology of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Olmsted County, Minnesota: A Twenty-Year US Population-Based Study.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>69</volume>
            <issue>12</issue>
            <fpage>2338</fpage>
            <page-range>2338-2350</page-range>
            <pub-id pub-id-type="pmid">28881446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Massicotte-Azarniouch</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Herrera</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Jennette</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Free</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of vascular damage in ANCA vasculitis.</article-title>
            <source>Semin Immunopathol</source>
            <year>2022</year>
            <month>May</month>
            <volume>44</volume>
            <issue>3</issue>
            <fpage>325</fpage>
            <page-range>325-345</page-range>
            <pub-id pub-id-type="pmid">35254509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frankel</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Schwarz</surname>
                <given-names>MI</given-names>
              </name>
            </person-group>
            <article-title>The pulmonary vasculitides.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2012</year>
            <month>Aug</month>
            <day>01</day>
            <volume>186</volume>
            <issue>3</issue>
            <fpage>216</fpage>
            <page-range>216-24</page-range>
            <pub-id pub-id-type="pmid">22679011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sun</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Mo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yue</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Clinical and pathological features of microscopic polyangiitis in 20 children.</article-title>
            <source>J Rheumatol</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>41</volume>
            <issue>8</issue>
            <fpage>1712</fpage>
            <page-range>1712-9</page-range>
            <pub-id pub-id-type="pmid">24986845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hauer</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Bajema</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>van Houwelingen</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Ferrario</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>No&#x000eb;l</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Waldherr</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bruijn</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Hagen</surname>
                <given-names>EC</given-names>
              </name>
              <collab>European Vasculitis Study Group (EUVAS)</collab>
            </person-group>
            <article-title>Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups.</article-title>
            <source>Kidney Int</source>
            <year>2002</year>
            <month>Jan</month>
            <volume>61</volume>
            <issue>1</issue>
            <fpage>80</fpage>
            <page-range>80-9</page-range>
            <pub-id pub-id-type="pmid">11786087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lababidi</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Odigwe</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Okolo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Elhassan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Iroegbu</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Microscopic polyangiitis causing diffuse alveolar hemorrhage and rapidly progressive glomerulonephritis.</article-title>
            <source>Proc (Bayl Univ Med Cent)</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>469</fpage>
            <page-range>469-71</page-range>
            <pub-id pub-id-type="pmid">26424944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Clinical features of children with pulmonary microscopic polyangiitis: report of 9 cases.</article-title>
            <source>PLoS One</source>
            <year>2015</year>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>e0124352</fpage>
            <pub-id pub-id-type="pmid">25923706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilke</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Prince-Fiocco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fiocco</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <article-title>Microscopic polyangiitis: a large single-center series.</article-title>
            <source>J Clin Rheumatol</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>179</fpage>
            <page-range>179-82</page-range>
            <pub-id pub-id-type="pmid">24847742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karras</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Microscopic Polyangiitis: New Insights into Pathogenesis, Clinical Features and Therapy.</article-title>
            <source>Semin Respir Crit Care Med</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>459</fpage>
            <page-range>459-464</page-range>
            <pub-id pub-id-type="pmid">30404112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barowka</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Perrine</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>"I'm coughing up blood".</article-title>
            <source>J Miss State Med Assoc</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>57</volume>
            <issue>11</issue>
            <fpage>354</fpage>
            <page-range>354-356</page-range>
            <pub-id pub-id-type="pmid">30281235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kluger</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pagnoux</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guillevin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Franc&#x000e8;s</surname>
                <given-names>C</given-names>
              </name>
              <collab>French Vasculitis Study Group</collab>
            </person-group>
            <article-title>Comparison of cutaneous manifestations in systemic polyarteritis nodosa and microscopic polyangiitis.</article-title>
            <source>Br J Dermatol</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>159</volume>
            <issue>3</issue>
            <fpage>615</fpage>
            <page-range>615-20</page-range>
            <pub-id pub-id-type="pmid">18647311</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lhote</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Guillevin</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome.</article-title>
            <source>Lupus</source>
            <year>1998</year>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>238</fpage>
            <page-range>238-58</page-range>
            <pub-id pub-id-type="pmid">9643314</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gibson</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous manifestations of antineutrophil cytoplasmic antibody-associated vasculitis (AAV): a concise review with emphasis on clinical and histopathologic correlation.</article-title>
            <source>Int J Dermatol</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>61</volume>
            <issue>12</issue>
            <fpage>1442</fpage>
            <page-range>1442-1451</page-range>
            <pub-id pub-id-type="pmid">35599359</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eriksson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Segelmark</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hallb&#x000f6;&#x000f6;k</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Frequency, Diagnosis, Treatment, and Outcome of Gastrointestinal Disease in Granulomatosis with Polyangiitis and Microscopic Polyangiitis.</article-title>
            <source>J Rheumatol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>45</volume>
            <issue>4</issue>
            <fpage>529</fpage>
            <page-range>529-537</page-range>
            <pub-id pub-id-type="pmid">29419474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hattori</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Misu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Koike</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ichimura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sobue</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Mortality and morbidity in peripheral neuropathy associated Churg-Strauss syndrome and microscopic polyangiitis.</article-title>
            <source>J Rheumatol</source>
            <year>2002</year>
            <month>Jul</month>
            <volume>29</volume>
            <issue>7</issue>
            <fpage>1408</fpage>
            <page-range>1408-14</page-range>
            <pub-id pub-id-type="pmid">12136898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Qu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Posterior Reversible Encephalopathy Syndrome in a Patient With Microscopic Polyangiitis: A Case Report and Literature Review.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2021</year>
            <volume>8</volume>
            <fpage>792744</fpage>
            <pub-id pub-id-type="pmid">35071272</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ku</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>HY</given-names>
              </name>
            </person-group>
            <article-title>Multiple bilateral non-hemorrhagic cerebral infarctions associated with microscopic polyangiitis.</article-title>
            <source>Clin Neurol Neurosurg</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>111</volume>
            <issue>10</issue>
            <fpage>904</fpage>
            <page-range>904-6</page-range>
            <pub-id pub-id-type="pmid">19733002</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eschun</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Mink</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary interstitial fibrosis as a presenting manifestation in perinuclear antineutrophilic cytoplasmic antibody microscopic polyangiitis.</article-title>
            <source>Chest</source>
            <year>2003</year>
            <month>Jan</month>
            <volume>123</volume>
            <issue>1</issue>
            <fpage>297</fpage>
            <page-range>297-301</page-range>
            <pub-id pub-id-type="pmid">12527637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Adachi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tabeya</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakagaki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yabana</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Goto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kondo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kasai</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Rare type of pancreatitis as the first presentation of anti-neutrophil cytoplasmic antibody-related vasculitis.</article-title>
            <source>World J Gastroenterol</source>
            <year>2016</year>
            <month>Feb</month>
            <day>21</day>
            <volume>22</volume>
            <issue>7</issue>
            <fpage>2383</fpage>
            <page-range>2383-90</page-range>
            <pub-id pub-id-type="pmid">26900301</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sassi</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Ghorbel</surname>
                <given-names>IB</given-names>
              </name>
              <name>
                <surname>Mizouni</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Houman</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Hentati</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Microscopic polyangiitis presenting with peripheral and central neurological manifestations.</article-title>
            <source>Neurol Sci</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>32</volume>
            <issue>4</issue>
            <fpage>727</fpage>
            <page-range>727-9</page-range>
            <pub-id pub-id-type="pmid">21681367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hellmich</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sanchez-Alamo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schirmer</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Berti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blockmans</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cid</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Holle</surname>
                <given-names>JU</given-names>
              </name>
              <name>
                <surname>Hollinger</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Karadag</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kronbichler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Little</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Luqmani</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Mahr</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Mohammad</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Monti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mukhtyar</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Musial</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Price-Kuehne</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Segelmark</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Teng</surname>
                <given-names>YKO</given-names>
              </name>
              <name>
                <surname>Terrier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tomasson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vaglio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vassilopoulos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Verhoeven</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2024</year>
            <month>Jan</month>
            <day>02</day>
            <volume>83</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <page-range>30-47</page-range>
            <pub-id pub-id-type="pmid">36927642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schirmer</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Sanchez-Alamo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hellmich</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Monti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Luqmani</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Tomasson</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1-treatment of granulomatosis with polyangiitis and microscopic polyangiitis.</article-title>
            <source>RMD Open</source>
            <year>2023</year>
            <month>Jul</month>
            <volume>9</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">37479496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jayne</surname>
                <given-names>DRW</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Schall</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Bekker</surname>
                <given-names>P</given-names>
              </name>
              <collab>ADVOCATE Study Group</collab>
            </person-group>
            <article-title>Avacopan for the Treatment of ANCA-Associated Vasculitis.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Feb</month>
            <day>18</day>
            <volume>384</volume>
            <issue>7</issue>
            <fpage>599</fpage>
            <page-range>599-609</page-range>
            <pub-id pub-id-type="pmid">33596356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Casal Moura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gauckler</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Anders</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Bruchfeld</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fernandez-Juarez</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Floege</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Frangou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Goumenos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Segelmark</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Turkmen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>van Kooten</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tesar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Geetha</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fervenza</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>DRW</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Kronbichler</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Management of antineutrophil cytoplasmic antibody-associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations.</article-title>
            <source>Nephrol Dial Transplant</source>
            <year>2023</year>
            <month>Oct</month>
            <day>31</day>
            <volume>38</volume>
            <issue>11</issue>
            <fpage>2637</fpage>
            <page-range>2637-2651</page-range>
            <pub-id pub-id-type="pmid">37164940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walsh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Collister</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Pusey</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Guyatt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Au Peh</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Szpirt</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ito-Hara</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>DRW</given-names>
              </name>
              <collab>Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis BMJ Rapid Recommendations Group</collab>
            </person-group>
            <article-title>The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis.</article-title>
            <source>BMJ</source>
            <year>2022</year>
            <month>Feb</month>
            <day>25</day>
            <volume>376</volume>
            <fpage>e064604</fpage>
            <pub-id pub-id-type="pmid">35217545</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ward</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Cosner</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Lamb</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Macknis</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Rooney</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>PL</given-names>
              </name>
            </person-group>
            <article-title>Top Differential Diagnosis Should Be Microscopic Polyangiitis in ANCA-Positive Patient with Diffuse Pulmonary Hemorrhage and Hemosiderosis.</article-title>
            <source>Case Rep Pathol</source>
            <year>2014</year>
            <volume>2014</volume>
            <fpage>286030</fpage>
            <pub-id pub-id-type="pmid">25525543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chotiyarnwong</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>McCloskey</surname>
                <given-names>EV</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment.</article-title>
            <source>Nat Rev Endocrinol</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>16</volume>
            <issue>8</issue>
            <fpage>437</fpage>
            <page-range>437-447</page-range>
            <pub-id pub-id-type="pmid">32286516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haldar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dru</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bhowmick</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of hemorrhagic cystitis.</article-title>
            <source>Am J Clin Exp Urol</source>
            <year>2014</year>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>199</fpage>
            <page-range>199-208</page-range>
            <pub-id pub-id-type="pmid">25374922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kitching</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Anders</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Basu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Brouwer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Kullman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lyons</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Savage</surname>
                <given-names>COS</given-names>
              </name>
              <name>
                <surname>Specks</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kain</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>ANCA-associated vasculitis.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2020</year>
            <month>Aug</month>
            <day>27</day>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>71</fpage>
            <pub-id pub-id-type="pmid">32855422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Doll</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Suppiah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Flossmann</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>H&#x000f6;glund</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mahr</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Westman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Luqmani</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>54</volume>
            <issue>3</issue>
            <fpage>471</fpage>
            <page-range>471-81</page-range>
            <pub-id pub-id-type="pmid">25205825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Doll</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Suppiah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Flossmann</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>H&#x000f6;glund</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jayne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mahr</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Westman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Luqmani</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>74</volume>
            <issue>1</issue>
            <fpage>177</fpage>
            <page-range>177-84</page-range>
            <pub-id pub-id-type="pmid">24243925</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25111.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stone</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Min</surname>
                <given-names>YI</given-names>
              </name>
              <name>
                <surname>Uhlfelder</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Hellmann</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Specks</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Spiera</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Calabrese</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Wigley</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Maiden</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Valente</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Niles</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Fye</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>McCune</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>St Clair</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Luqmani</surname>
                <given-names>RA</given-names>
              </name>
              <collab>International Network for the Study of the Systemic Vasculitides (INSSYS)</collab>
            </person-group>
            <article-title>A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS).</article-title>
            <source>Arthritis Rheum</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>44</volume>
            <issue>4</issue>
            <fpage>912</fpage>
            <page-range>912-20</page-range>
            <pub-id pub-id-type="pmid">11318006</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
